Linawise -D 5/10

 Linawise-D 5/10 is an advanced dual-combination therapy designed for effective management of type 2 diabetes mellitus. It combines the benefits of Linagliptin, a DPP-4 inhibitor, and dapagliflozin, an SGLT2 inhibitor, to support comprehensive glycemic control.

Linagliptin helps increase insulin secretion and decrease glucagon levels in a glucose-dependent manner, while dapagliflozin works by removing excess glucose through urine by inhibiting glucose reabsorption in the kidneys.

This combination helps improve fasting and postprandial blood sugar levels and may also support weight management and cardiovascular health in appropriate patients. Linagliptin  increases natural incretin substances that lower blood sugar. Dapagliflozin prevents the kidneys from reabsorbing glucose, allowing it to be excreted in the urine.

How does Linawise-D 5/10 (linagliptin 5 mg + dapagliflozin 10 mg) work?

Linagliptin (DPP-4 Inhibitor):

Competitively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme.

Increases the levels of active incretin hormones, such as GLP-1 (glucagon-like peptide-1).

Enhances insulin release and decreases glucagon secretion in a glucose-dependent manner, particularly after meals (postprandial).

Dapagliflozin (SGLT-2 Inhibitor):

Selectively inhibits sodium-glucose co-transporter-2 (SGLT-2) in the proximal renal tubules.

Reduces renal reabsorption of glucose, lowering the renal threshold for glucose.

Increases urinary glucose excretion (glucosuria), leading to reduced plasma glucose levels. 

Clinical Benefits

 It combines DPP-4 inhibition (linagliptin increases insulin and decreases glucagon) with SGLT2 inhibition (dapagliflozin removes glucose via urine), lowering both fasting and post-meal glucose effectively.

Reduces heart failure hospitalizations and protects kidney function, which is critical for high-risk T2DM patients.

The dapagliflozin component helps decrease weight by excreting excess calories, a common benefit for patients managing metabolic health.

Linagliptin provides a safe insulin-boosting effect with a low risk of lowering blood sugar too much.

Dosage & Administration

Linawise-D 5/10 (Linagliptin 5mg + Depagliflozin 10mg) The tablet should be taken as directed by the physician. The usual recommended dose is one tablet once daily, with or without food. Dosage may vary depending on the patient’s clinical condition, blood glucose levels, and response to treatment. Patients are advised to maintain proper hydration and follow recommended dietary and lifestyle modifications during therapy.

Disclaimer

The information provided herein is intended for educational and informational purposes only and should not be considered as medical advice. Linawise-D 5/10 (Linagliptin 5mg + Depagliflozin 10mg) The tablet should be used strictly under the supervision of a qualified healthcare professional. Please read the package insert carefully before use. Keep out of reach of children.